Genetic Engineering & Biotechnology News

Cmbio Launches to Provide a Centralized Hub for Microbiome and Metabolomics Services The new business combines Clinical Microbiomics, CosmosID, MS-Omics, DNASense, and Microba Life Sciences. The combined company has a team of over 100 experts in microbiome and metabolome science and will provide GxP lab services, advanced bioinformatics, and multiomics solutions that support research in human, animal, and planetary health.

Spatial and Single-Cell Data Combined to Create Comprehensive Cell Map of the Human Gut Mapping these cells can provide further insights into what happens in conditions such as bowel #cancer and IBD. Using this atlas, the Wellcome Sanger Institute researchers and collaborators uncovered a new role of a specific gut cell, highlighting its contributions to a cycle of inflammation in some individuals, possibly causing pain and distress.

NEW WEBINAR! Is Biopharma Ready for AI? Exploring Tech Strategies Across Large and Small Biopharma Wednesday, December 4, 2024 8:00 am PT, 11:00 am ET, 17:00 CET In this GEN webinar, experts from AbbVie (Mohit Agnihotri) and Benchling (Lauren DeVos) will share insights into the current tech landscape, AI readiness, and the strategies for digital transformation shaping large and small biopharma. Register now to join us for this free webinar sponsored by Benchling: https://hubs.li/Q02YYhFL0 #AI #DrugDiscovery

Abzena Expands Analytical Capabilities to Include GMP Cell-Based Potency Testing Abzena maintains that it will be able to provide precise and reliable data on drug potency, alongside developability and characterization data including mechanism of action (MOA) and immunogenicity, which are essential for regulatory submissions.

Asimov and RevOpsis Therapeutics Ink Licensing Deal for Multispecific-Expressing Cell Line The agreement follows a cell line development campaign with Asimov’s CHO Edge System for the lead RevOpsis asset, RO-104.

Schrödinger, Novartis Ink Up-to-$2.3B Collaboration, Software Agreement The collaboration and license agreement with Schrödinger aims to advance “multiple” small molecule candidates into Novartis’ portfolio for further development.

Are Single Cells Capable of a Simple Form of Learning? Researchers at the Centre for Genomic Regulation (CRG), and at Harvard Medical School have used mathematical modeling to show how individual cells appear capable of learning. Results from their studies could represent an important shift in how we view the fundamental units of life.

Aggressive Tumor Growth in Drug-Resistant Prostate Cancer Driven by Enzyme The absence of a protein called PKCλ/ι in prostate cancer cells enables the enzyme EZH2 to drive aggressive growth, even with androgen receptor inhibitors present. The findings could potentially lead to new therapies. The study was led by Maria T. Diaz-Meco, PhD, and Jorge Moscat, PhD, both Homer T. Hirst III Professors of Oncology in Pathology and members of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.

Ireland’s SSPC and NIBRT Team to Take on Biopharma Bottlenecks Process development will be another focus. SSPC, Research Ireland Centre for Pharmaceuticals and NIBRT National Institute for Bioprocessing Research and Training will use hybrid mechanistic-machine learning models to investigate current processing bottlenecks such as variability in biotherapeutic productivity.

Enhancing Value in Advanced Therapy Manufacturing Cell and gene therapy companies should work to convince healthcare systems of the value of their therapies, as well as improving the efficiency of their manufacturing processes.